Tumour-Infiltrating Inflammatory Cells in Early Breast Cancer: An Underrated Prognostic and Predictive Factor?
Overview
Chemistry
Molecular Biology
Authors
Affiliations
The role of tumour-infiltrating inflammatory cells (TIICs) in the disease progression of hormone-receptor-positive breast cancer (HR+ BC) is largely unclear since it is generally regarded as the least immunogenic BC subtype. This study investigated the prognostic significance of CD1a+ dendritic cells, CD20+ B cells, CD45RO+ memory T cells and CD4+ T-helper cells in HR+ BC. One hundred and forty-six patients were treated for early stage, distant-metastases-free HR+ BC in an accelerated partial breast irradiation (APBI) phase II trial. Immunohistochemistry was used to double-stain two adjoining sets of tissue microarrays from pre-RT (radiotherapy) tumour resection samples for CD1a/CD20 and CD45RO/CD4. Cell densities of CD1a+, CD20+, CD45RO+ and CD4+ TIICs in the stromal and intraepithelial compartment were registered semiautomatically. High densities of CD20+ and CD4+ TIICs were strongly associated with reduced disease-free survival (DFS), while high stromal CD45RO+ TIIC densities were indicators of subsequent successful treatment. An immunoscore based on CD20+ and CD45RO+ TIIC densities identified three different risk groups ( < 0.001). Thus, contrary to current assumptions, intratumoural immune cell composition might be an important prognostic indicator and a possible contributing factor in the outcome of HR+ BC and should be the subject of further research. Specifically, B-cell infiltration entailed an increased relapse rate and could play an important role in disease progression.
Naji O, Ghouzlani A, Rafii S, Sadiqi R, Kone A, Harmak Z Front Immunol. 2024; 15:1399754.
PMID: 39507526 PMC: 11538072. DOI: 10.3389/fimmu.2024.1399754.
Schmidt E, Distel L, Erber R, Buttner-Herold M, Rosahl M, Ott O Cancers (Basel). 2024; 16(18).
PMID: 39335132 PMC: 11430230. DOI: 10.3390/cancers16183160.
Galadima M, Teles M, Pastor J, Hernandez-Losa J, Rodriguez-Gil J, Rivera Del Alamo M Int J Mol Sci. 2024; 25(2).
PMID: 38256245 PMC: 10816983. DOI: 10.3390/ijms25021170.
Li B, Wang K, Shi S, Li M, Ma M, Zhou Z Saudi Med J. 2023; 44(11):1104-1112.
PMID: 37926448 PMC: 10712764. DOI: 10.15537/smj.2023.44.11.20220946.
Zareinejad M, Mehdipour F, Roshan-Zamir M, Faghih Z, Ghaderi A Cancers (Basel). 2023; 15(19).
PMID: 37835465 PMC: 10571747. DOI: 10.3390/cancers15194771.